Ultra-LEAF™ Purified anti-human CD27 Antibody, CD27, W22076F,BioLegend,636553

Host

Rat

Reactivity

Human

Application

Block - Quality tested

Platform ID

BAB086725232

BioLegend

Headquarters

8999 BioLegend Way San Diego, CA 92121 United States

Contact

Tel: 1-858-455-9588
Fax: +49 (4131) 7023913

Email:

Product Specifications
Scientific Background

Specifications

NameUltra-LEAF™ Purified anti-human CD27 Antibody, CD27, W22076F
Cat. No.636553
HostRat
RRIDAB_3106082 (BioLegend Cat. No. 636553)AB_3106082 (BioLegend Cat. No. 636554)
IsotypeRat IgG2a, κ
ReactivityHuman
ApplicationBlock - Quality tested
ClonalityMonoclonal
Clone NumberW22076F
ConcentrationThe antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in ourCertificate of Analysisonline tool.
TargetCD27
ImmunogenRecombinant human CD27 (TNFRSF7)-Fc chimera
PurityThe Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Formulation0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
StorageThe antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Regulatory StatusResearch Use Only

Scientific Background

CD27 (TNFRSF7) is a member of the TNFR family. It is a type I membrane glycoprotein with a MW of 55KDa that forms a disulfide linked homodimer. The receptor possesses three cysteine rich repeats in the extracellular domain, the transmembrane region, and the intracellular domain. CD27 binds CD27L (CD70), another member of the TNF ligand family that forms a trimer; thus, it has been speculated that the CD27L binds to a trimeric structure composed by three dimeric CD27 molecules. The interaction between CD27 and its ligand, CD70, plays a role in providing co-stimulation for prolonged lymphocyte survival, enhanced T-cell proliferation, and memory-cell formation. T cells expressing CD27 and CD70 play a key role in regulating B-cell activation and immunoglobulin synthesis. Soluble CD27 (sCD27), the extracellular domain of membrane-bound CD27, can be released after lymphocyte activation by differential splicing of the receptor protein or shedding from the cell surface by metalloproteinases (MMPs). Soluble CD27 has been detected in serum, plasma, and urine samples from healthy individuals, and it has been described elevated sCD27 levels in serum of patients with systemic lupus erythematosus, viral infections, and lymphoid malignancies. The sCD27-pool in cancer patients can be significantly enlarged by immunotherapy. CD27 is recognized as a marker for memory B cells and is considered of diagnostic value in patients who have decreased numbers of switched memory B cells.

Category Paths

Request a product

Please provide the required information below so that we can quickly source your products.